RT Journal Article
SR Electronic
T1 SARS-CoV2 sero-survey among adults involved in health care and health research in Guinea-Bissau, West Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.06.21253046
DO 10.1101/2021.03.06.21253046
A1 Benn, Christine Stabell
A1 Salinha, Alberto
A1 Mendes, Sabado
A1 Cabral, Carlos
A1 Martins, Cesario
A1 Nielsen, Sebastian
A1 Bærent Fisker, Ane
A1 Schaltz-Buchholzer, Frederik
A1 Sværke Jørgensen, Charlotte
A1 Aaby, Peter
YR 2021
UL http://medrxiv.org/content/early/2021/03/08/2021.03.06.21253046.abstract
AB Background Many African countries have reported fewer COVID-19 cases than countries elsewhere. By the end of 2020, Guinea-Bissau, West Africa, had <2500 PCR-confirmed cases corresponding to 0.1% of the ∼1.8 million national population. We assessed the prevalence of SARS-CoV2 antibodies in urban Guinea-Bissau.Methods We measured IgG antibody in point-of-care rapid tests among 140 staff and associates at a biometric research field station in Bissau, the capital of Guinea-Bissau, during November 2020.Results Of 140 participants, 25 (18%) were IgG-positive. Among IgG-positives, 12 (48%) reported an episode of illness since the onset of the pandemic. Twenty-five (18%) participants had been PCR-tested between May and September; 7 (28%) were PCR-positive. Four of these 7 tested IgG-negative in the present study. Five participants reported a death in their house, corresponding to a crude annual death rate of 4.5/1000 people; no death was attributed to COVID-19.Conclusions In spite of low official number of COVID-19 cases, our serosurvey found a high prevalence of IgG-positivity. Most IgG-positives had not been ill. The official number of PCR-confirmed COVID-19 cases grossly underestimates the prevalence during the pandemic. The observed overall mortality rate is not higher than the official Guinean mortality rate of 9.6/1000 people.Competing Interest StatementThe authors have declared no competing interest.Funding StatementEDCTP funded a study of BCG vaccine to health care workers including part of the staff involved in the present survey (RIA2020EF-3049). Statens Serum Institut, Denmark, donated the test kits used while other expenses were covered by in-kind funding. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Guinean National Ethics Committee (Ref 116/CNES/INASA/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReg. data sharing, please contact the corresponding author.